Zimmer Biomet Holdings Asia Pacific — Operating Income decreased by 20.6% to $93.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 4.7%, from $88.80M to $93.00M. Over 4 years (FY 2021 to FY 2025), Asia Pacific — Operating Income shows relatively stable performance with a 1.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Higher operating income indicates strong regional profitability and effective cost management.
The profit or loss generated by the Asia Pacific segment after deducting cost of goods sold, SG&A, and R&D expenses from...
Standard segment-level profitability metric for all public companies.
zbh_segment_asia_pacific_operating_income_loss| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $105.50M | $106.70M | $92.40M | $93.40M | $110.00M | $103.60M | $118.90M | $90.20M | $115.30M | $112.50M | $119.00M | $94.40M | $122.20M | $123.40M | $122.10M | $88.80M | $122.90M | $116.60M | $117.20M | $93.00M |
| QoQ Change | — | +1.1% | -13.4% | +1.1% | +17.8% | -5.8% | +14.8% | -24.1% | +27.8% | -2.4% | +5.8% | -20.7% | +29.4% | +1.0% | -1.1% | -27.3% | +38.4% | -5.1% | +0.5% | -20.6% |
| YoY Change | — | — | — | — | +4.3% | -2.9% | +28.7% | -3.4% | +4.8% | +8.6% | +0.1% | +4.7% | +6.0% | +9.7% | +2.6% | -5.9% | +0.6% | -5.5% | -4.0% | +4.7% |